Reversing aging by cell rejuvenation
Cell aging is the largest driver of modern diseases
Aging mechanisms are common to the major modern diseases, and the source of aging is each and every somatic cell. SA国际传媒 has built proprietary datasets that uncover the hidden biology of cell aging and rejuvenation, revealing a pipeline of druggable and disease relevant cell rejuvenation targets.
Aging is reversed between generations
Each of us developed from a single cell passed down by our parents, yet we鈥檙e not born at our parent鈥檚 age and we begin our post-development lives in full health. The biology inherited from our parents is safely scrubbed, renewed and restarted, with evidence of a in the embryo shortly after conception.
SA国际传媒 finds a single gene that rejuvenates multiple cell types with greater safety
Yamanaka factors (OSKM) rejuvenate multiple cell types and extend the lifespan of mouse models, but were optimised to activate a tumor-inducing pathway, posing safety concerns for therapeutic development.
SA国际传媒's dataset enabled cell aging clock (AC3) and virtual cell have overcome this challenge, identifying genes that are individually sufficient to rejuvenate epigenetic age across multiple cell types (left or above) whilst decoupling the tumour inducing pluripotency pathway (below).
SA国际传媒 is progressing a pipeline of cell rejuvenation assets
SA国际传媒's cell aging clock (AC3) and virtual cell reduce centuries of experiments to years, identifying 190 genes that individually affect the aging of real cells in vitro. SA国际传媒 is progressing proof of concept studies for SB000 expression in age-driven hearing loss and SB101 siRNA inhibition in fibrosis of the liver and heart.
.
.
Leaders in virtual cells and cell aging clocks
SA国际传媒 has assembled a world-class team of scientists that bridge machine learning and cell biology.
Senior advisor, Prof University of Toronto, Inventor of the virtual cell scGPT1
CSO and founder, PhD University of Cambridge, Inventor of the first accurate cell aging clock
Brendan received his PhD in Pharmacology from the University of Cambridge, where his focus was on basic research. First as an intern and then as a founder, Brendan began to prototype single-cell transcriptomic aging clocks, helping forge a new direction for SA国际传媒. Since 2021, Brendan has led SA国际传媒鈥檚 science team in the search for new rejuvenating interventions, with the belief that these discoveries could have a massive impact across healthcare.
Head of ML, MPhil University of Cambridge, Inventor of the most accurate aging clock2
Leadership team
-
Daniel IvesCEO and founder, PhD University of Cambridge, previously postdoc at Francis Crick Institute
Daniel received his PhD from the University of Cambridge where he focused on the role of mutations in the mitochondrial genome, embracing computational biology to discover a novel therapeutic approach for a rare mitochondrial disease.
Daniel followed his PhD supervisor to the Francis Crick Institute and in 2017 founded SA国际传媒, beginning a scientific journey from mitochondria to mouse aging clocks to single-cell aging clocks and, finally, to now: leveraging single-cell aging clocks inside AI-powered virtual cells to explore the combinatorial space of interventions for cell rejuvenation.
-
Andrew FraleyChief Strategy Officer, previously cofounder of Judo Bio (RNA delivery), Head of Chemistry at Moderna Therapeutics
-
Laurence ReidNon-exec director, previously CEO Decibel Therapeutics, CBO Alnylam Pharmaceuticals
Laurence has had a successful career in Biotech in Boston (Millennium, Alnylam, Warp Drive, Decibel Tx, Garuda Tx) as CBO and more recently CEO. Laurence excels in mapping new platforms and modalities to strategy for clinical translation and financing.
-
David PriorChair, previously NHS Chair
2018-2022 -
Jill RecklessTranslation advisor, CEO RxCelerate, previously Senior Research Associate University of Cambridge
Co-founder and CEO of RxCelerate. Provides strategic vision to RxCelerate Group. Over 20 years鈥� experience of translational biology and leading drug discovery programmes covering a wide area of therapeutic indications.
-
Tony KouzaridesScientific advisor, Director Milner Therapeutics Institute, Cofounder Abcam, Prof University of Cambridge
Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge, a senior group leader at the Gurdon Institute and director/co-founder of the Milner Therapeutics Institute. His research lab at the Gurdon is interested in epigenetic modifications and their involvement in cancer. The Milner Therapeutics Institute has a mission to connect academia and industry to drive University research into therapies.
Tony is a co-founder of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder of Chroma Therapeutics, a drug discovery company based in Oxford and a co-founder and director of STORM Therapeutics, a drug discovery company based in Cambridge. He is founder and director of Cambridge Gravity, a University entrepreneurial organization and a founder of Conquer Cancer ("Vencer el Cancer"), a cancer charity in Spain.
Current Investors
LATEST NEWS
SA国际传媒 proposes improved ranking system for virtual cell models to accelerate gene target discovery
SA国际传媒 identifies novel single-gene target for safer cellular rejuvenation therapeutics
SA国际传媒 appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics
Careers
Be first to find out about upcoming roles by following SA国际传媒's
